Abstract
Hyperlipidemia, hypertension, and diabetes mellitus (DM) are well-established risk factors for cardiovascular disease. We analyzed the cardiovascular events in hyperlipidemic patients with or without DM who were administered open-labeled simvastatin in groups stratified by blood pressure level using data from the Japan Lipid Intervention Trial (J-LIT). Hyperlipidemic patients with DM (n=6,288) had significantly more cardiovascular events than those without DM (n=33,933). The incidence rates of total cardiovascular events in the Non-DM and DM groups were 15.40 and 25.76 per 1,000 patients for the 6-year period, respectively. The relative risk of total cardiovascular events in the DM vs. the Non-DM group was 1.68, and the relative risk was significantly higher in the DM than in the Non-DM group. The relative risks of total cardiovascular events were significantly higher in DM and Non-DM patients whose systolic blood pressure (SBP) was greater than or equal to 130 mmHg compared to that of Non-DM patients whose SBP was less than 130 mmHg, and in DM and Non-DM patients whose diastolic blood pressure (DBP) was greater than or equal to 80 mmHg compared to that of Non-DM patients whose DBP was less than 80 mmHg. In all groups stratified by SBP and DBP, relative risks of total cardiovascular events were higher in DM patients than in Non-DM patients. For patients with hypercholesterolemia and DM, blood pressure should be strictly controlled in order to prevent both coronary events and stroke. These results are in good agreement with the JNC 7 and the ESH/ESC guidelines for DM patients, which recommended that the SBP and DBP be less than 130 and 80 mmHg, respectively.
Similar content being viewed by others
Article PDF
References
Howard BV, Rodrigues BL, Bennett PH, et al: Diabetes and cardiovascular disease: Writing Group I: epidemiology. Circulation 2002; 105: e132–e137.
Goldstein LB, Adams R, Becker K, et al: Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163–182.
Stamler J, Vaccaro O, Neaton JD, Wentworth D : Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444.
Fujishima M, Kiyohara Y, Kato I, et al: Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996; 45: S14–S16.
Kannel WB, McGee D, Gordon T : A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46–51.
Stamler J, Stamler R, Neaton JD : Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598–615.
Stegmayr B, Asplund K, Kuulasmaa K, Rajakangas AM, Thorvaldsen P, Tuomilehto J : Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project: an ecological study of 18 populations. Stroke 1997; 28: 1367–1374.
He J, Whelton PK : Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138: 211–219.
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Arch Intern Med 1997; 157: 2413–2446.
Guidelines Sub-Committee : 1999 World Health Organization–International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.
Hansson L, Zanchetti A, Carruther SG, et al, HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Matsuzawa Y, Itakura H, Kita T, et al: Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: the Japan Lipid Intervention Trial (J-LIT). Curr Ther Res 2000; 61: 219–243.
Matsuzawa Y, Kita T, Mabuchi H, et al: Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003; 67: 287–294.
Matsuzaki M, Kita T, Mabuchi H, et al: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087–1095.
Oikawa S, Kita T, Mabuchi H, et al: Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis 2007 ( in press, online available).
Nakaya N, Kita T, Mabuchi H, et al: Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT). Circ J 2005; 69: 1016–1021.
Kuzuya T, Nakagawa S, Satoh J, et al: Report of the Committee of Japan Diabetes Society on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Jpn Diab Soc 1999; 42: 385–404.
Shimamoto K, Kita T, Mabuchi H, et al: The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) study, a large-scale observational cohort study. Hypertens Res 2005; 28: 879–887.
Arauz-Pacheco C, Parrott MA, Raskin P : Hypertension management in adults with diabetes. Diabetes Care 2004; 27: S65–S67.
European Society of Hypertension–European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Shimamoto, K., Kita, T., Mabuchi, H. et al. Effects of Hypertension and Type 2 Diabetes Mellitus on the Risk of Total Cardiovascular Events in Japanese Patients with Hypercholesterolemia: Implications from the Japan Lipid Intervention Trial (J-LIT). Hypertens Res 30, 119–123 (2007). https://doi.org/10.1291/hypres.30.119
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.119